Therapeutic Targeting of the Pentose Phosphate Pathway in Colorectal Cancer Using 6‐Aminonicotinamide and 5‐Fluorouracil
Molecular Carcinogenesis · 2025-07 · 64 (7) · 1222-1235
DOI: 10.1002/mc.23920 ↗At a glance
Journal article in Molecular Carcinogenesis, published online on 2025-04-16. Written by Israa Ahmad Cheikh and 8 co-authors. Institution: Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon. Major MEDLINE topics: Fluorouracil, Pentose Phosphate Pathway, Colorectal Neoplasms, 6-Aminonicotinamide. Cited 5 times so far (Crossref); 29 references. Funded by: This research was supported by the Medical Practice Plan and the University Research Board of the American University of Beirut in Lebanon to N.D.11.543819.511….
Abstract (original language)
Colorectal cancer (CRC) is a significant global health concern with rising incidence and mortality rates. 5‐Fluorouracil (5‐FU) is the standard chemotherapy for CRC but is often constrained by resistance and toxicity, highlighting the need for more efficient treatments. The pentose phosphate pathway (PPP), a glucose metabolic shunt, is significantly upregulated in CRC to support nucleotide synthesis and redox balance. Therefore, we hypothesized that targeting the PPP decreases CRC cell growth, reduces tumor progression, and improves 5‐FU therapy. Consequently, we investigated the anti‐tumor activities, cell death mechanism, and mode of action of the PPP inhibitor, 6‐aminonicotinamide (6‐AN), and 5‐FU alone or in combination against CRC. We used human CRC cell lines with different p53 and 5‐FU resistance statuses and a CRC xenograft model. Our findings show that 6‐AN reduced the viability of human CRC cells independently of their p53 and 5‐FU resistance profile, with its effect further enhanced in combination with 5‐FU. The 6‐AN/5‐FU combination treatment synergized by reducing the total dehydrogenase activity of the PPP, inducing oxidative stress, and promoting senescence in CRC cells. Furthermore, 6‐AN treatment significantly decreased tumor growth in a CRC xenograft mouse model. However, combining 6‐AN with 5‐FU did not reduce tumor volume significantly, highlighting the complexities of translating in vitro findings to animal models. These results suggest that interfering with the PPP activity suppresses CRC cell growth and may reduce 5‐FU resistance. This study underscores targeting cancer metabolism as a novel therapeutic strategy to minimize drug resistance and to improve CRC therapeutic outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
- Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon.
ORCID profiles: Nadine Darwiche
Funding
- This research was supported by the Medical Practice Plan and the University Research Board of the American University of Beirut in Lebanon to N.D.11.543819.511…
Cite
APA
Cheikh, I. A., Hayar, B., Ghanem, N., Saleh, L. A., El-Baba, C., Al-Hadeethi, S., El-Khoury, R., Usta, J., & Darwiche, N. (2025). Therapeutic Targeting of the Pentose Phosphate Pathway in Colorectal Cancer Using 6‐Aminonicotinamide and 5‐Fluorouracil. Molecular Carcinogenesis, 64(7), 1222-1235. https://doi.org/10.1002/mc.23920
Vancouver
Cheikh IA, Hayar B, Ghanem N, Saleh LA, El-Baba C, Al-Hadeethi S, et al. Therapeutic Targeting of the Pentose Phosphate Pathway in Colorectal Cancer Using 6‐Aminonicotinamide and 5‐Fluorouracil. Molecular Carcinogenesis. 2025;64(7):1222-1235. doi:10.1002/mc.23920
BibTeX
@article{Cheikh2025,
author = {Cheikh, Israa Ahmad and Hayar, Berthe and Ghanem, Noorhan and Saleh, Lara Al and El-Baba, Chirine and Al-Hadeethi, Sadaf and El-Khoury, Riyad and Usta, Julnar and Darwiche, Nadine},
title = {Therapeutic Targeting of the Pentose Phosphate Pathway in Colorectal Cancer Using 6‐Aminonicotinamide and 5‐Fluorouracil},
journal = {Molecular Carcinogenesis},
year = {2025},
volume = {64},
number = {7},
pages = {1222--1235},
doi = {10.1002/mc.23920}
}
EUVIMED